Dorchester Minerals, L.P. Announces Its First Quarter Distribution
DALLAS, April 24, 2025 (GLOBE NEWSWIRE) — Dorchester Minerals, L.P. (NASDAQ:DMLP) announced today the Partnership's first quarter 2025 cash distribution. The distribution of $0.725835 per common unit represents activity for the three-month period ended March 31, 2025 and is payable on May 15, 2025 to common unitholders of record as of May 5, 2025.
Cash receipts attributable to the Partnership's Royalty Properties during the first quarter totaled approximately $34.2 million. Approximately 68% of these receipts reflect oil sales during December 2024 through February 2025 and natural gas sales during November 2024 through January 2025, and approximately 32% from prior sales periods. Cash Receipts attributable to the Partnership's Net Profits Interest during the first quarter totaled approximately $4.8 million. Approximately 74% of these receipts reflect oil sales and natural gas sales during November 2024 through January 2025, and approximately 26% from prior sales periods.
Cash receipts attributable to lease bonus and other income during the first quarter totaled approximately $0.6 million.
Dorchester Minerals, L.P. is a Dallas-based owner of producing and non-producing oil and natural gas mineral, royalty, overriding royalty, net profits, and leasehold interests located in 28 states. Its common units trade on the Nasdaq Global Select Market under the symbol DMLP.
This release serves as qualified notice to nominees as provided for under Treasury Regulation Section 1.1446-4(b)(4) and (d). Although a portion of Dorchester Minerals, L.P.'s income may not be effectively connected income and may be subject to alternative withholding procedures, brokers and nominees should treat 100% of Dorchester Minerals, L.P.'s distributions to non-U.S. investors as being attributable to income that is effectively connected with a United States trade or business. Accordingly, Dorchester Minerals, L.P.'s distributions to non-U.S. investors are subject to federal income tax withholding at the highest marginal rate for individuals or corporations, as applicable. Nominees, and not Dorchester Minerals, L.P., are treated as withholding agents responsible for withholding on distributions received by them on behalf of non-U.S. investors.
FORWARD-LOOKING STATEMENTS
Portions of this document may constitute 'forward-looking statements' as defined by federal law. Such statements are subject to certain risks, uncertainties and assumptions. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, estimated or projected. Examples of such uncertainties and risk factors include, but are not limited to, changes in the price or demand for oil and natural gas, changes in the operations on or development of the Partnership's properties, changes in economic and industry conditions and changes in regulatory requirements (including changes in environmental requirements) and the Partnership's financial position, business strategy and other plans and objectives for future operations. These and other factors are set forth in the Partnership's filings with the Securities and Exchange Commission.
Contact: Martye Miller 3838 Oak Lawn Ave., Suite 300 Dallas, Texas 75219-4541
(214) 559-0300
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Wall Street Journal
5 minutes ago
- Wall Street Journal
Recognize Raises $1.7 Billion for Second Tech-Services Fund
Recognize Partners, a private-equity firm co-founded by former Clayton, Dubilier & Rice executive David Wasserman, has closed its second fund with $1.7 billion. The final tally for Recognize Partners II surpassed the $1.3 billion the New York-based firm raised for its debut fund.
Associated Press
9 minutes ago
- Associated Press
Total number of shares and voting rights in Zealand Pharma as of June 30, 2025
Company announcement – No. 16 / 2025 Total number of shares and voting rights in Zealand Pharma as of June 30, 2025 Copenhagen, Denmark, June 30, 2025 – Zealand Pharma A/S ('the Company' or 'Zealand Pharma') (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces, in accordance with section 32 of the Danish Capital Markets Act, the total number of shares and voting rights in the Company at the end of a calendar month during which changes to its share capital have occurred. In Company Announcement No. 14 / 2025 dated June 6, 2025, Zealand Pharma announced a share capital increase due to the exercise of employee warrants. Following this announcement, the table below details the total number of shares and voting rights in Zealand Pharma as of June 30, 2025. The Company's Articles of Association are available on the Company's website # # # About Zealand Pharma A/S Zealand Pharma A/S (Nasdaq: ZEAL) ('Zealand') is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharmaceutical companies as well as commercial partnerships for its marketed products. Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the United States. For more information about Zealand's business and activities, please visit Contact Adam Lange (Investors) Vice President, Investor Relations [email protected] Neshat Ahmadi (Investors) Investor Relations Manager [email protected] Anna Krassowska (Investors and Media) Vice President, Investor Relations & Corporate Communications [email protected]
Associated Press
9 minutes ago
- Associated Press
DEADLINE ALERT for RCKT, DDD, TEM: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions
BENSALEM, Pa., June 30, 2025 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion. Investors suffering losses on their investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in these class actions at (215) 638-4847 or by email to [email protected]. Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT ) Class Period: February 27, 2025 – May 26, 2025 Lead Plaintiff Deadline: August 11, 2025 The complaint alleges that throughout the Class Period the defendants made false and/or misleading statements and/or failed to disclose that: (1) Rocket knew SAEs, including death of participants enrolled in the study, were a risk; (2) Rocket amended the trial's protocol to introduce a novel immunomodulatory agent to the pretreatment regimen without providing this critical update to shareholders; and (3) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. 3D Systems Corporation (NYSE: DDD ) Class Period: August 13, 2024 – May 12, 2025 Lead Plaintiff Deadline: August 12, 2025 The complaint alleges that throughout the Class Period the defendants made false and/or misleading statements and/or failed to disclose that: (1) 3D Systems had understated the impact of weakened customer spending on the Company's business, while overstating its resilience in challenging industry conditions; (2) the updated milestone criteria in the United Partnership would negatively impact the Company's Regenerative Medicine Program revenue; and (3) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. Tempus AI, Inc. (NASDAQ: TEM ) Class Period: August 6, 2024 – May 27, 2025 Lead Plaintiff Deadline: August 12, 2025 The complaint alleges that throughout the Class Period the defendants made false and/or misleading statements and/or failed to disclose that: (1) Tempus inflated the value of contract agreements, many of which were with related parties, included non-binding opt-ins and/or were self-funded; (2) the credibility and substance of the joint venture with SoftBank was at risk because it gave the appearance of 'round-tripping' capital to create revenue for Tempus; (3) Tempus-acquired Ambry had a business model based on aggressive and potentially unethical billing practices that risked scrutiny and unsustainability; (4) AstraZeneca had reduced its financial commitments to Tempus through a questionable 'pass-through payment' via a joint agreement between it, the Company and Pathos AI; (5) the foregoing issues revealed weakness in core operations and revenue prospects; and (6) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. To be a member of these class actions, you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about these class actions, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215) 638-4847 or by email to [email protected], or visit our website at This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Contacts Law Offices of Howard G. Smith Howard G. Smith, Esquire 215-638-4847 888-638-4847 [email protected]
